Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients

Journal of Viral Hepatitis

Volumn 17, Issue SUPPL. 1, 2010, Pages 59-65

  Lu, H Y ^a   Zhuang, L W ^b   Yu, Y Y ^a   Si, C W ^a  

^a PEKING UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Covalently closed circular DNA; Hepatitis B virus; Interferon 2b; Lamivudine; Virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA VIRUS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGICAL RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BLOOD; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; LIVER; MALE; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77749308549     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01272.x     Document Type: Article

References (29)

1. World Health Organization. Fact sheets WHO/204: Hepatitus B. Geneva : World Health Organization, 2000.
2. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001 120 : 1828 1853.
3. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005 352 : 2682 2695.
4. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004 351 : 1206 1217.
5. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 341 : 1256 1263.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005 352 : 2673 2681.
7. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006 354 : 1001 1010.
8. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine mfor patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 354 : 1011 1020.
9. Reijnders JG, Leemans WF, Hansen BE et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J Viral Hepat 2009 16 (2 113 120.
10. Leung N, Peng CY, Hann HW et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009 49 (1 72 79.
11. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008 49 (4 634 651.
12. Yang W, Summers J. Integration of hepadnavirus DNA in infected liver: evidence for a linear precursor. J Virol 1999 73 : 9710 9717.
13. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005 42 : 302 308.
14. Yuen MF, Wong DK, Sum SS et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol 2005 100 (5 1099 1103.
15. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004 126 (7 1750 1758.
16. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006 11 (7 909 911.
17. Lu HY, Zhuang LW, Yu YY, Si CW, Zeng Z, Li J. Effects of antiviral agents and HBV genotypes on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2008 14 (8 1268 1273.
18. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 1 : 431 435.
19. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 1993 119 : 312 323.
20. Cooksley WG, Piratvisuth T, Lee SD et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e entigen-positive chronic hepatitis B. J Viral Hepat 2003 10 : 298 305.
21. Liaw Y-F, Leung N, Kao J-H et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008 2 : 263 283.
22. Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008 2 : 163 178.
23. Locarnini S. Primary resistance, multidrug resistance and crossresistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008 10 : 9048 9053.
24. Gane E. The roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int 2008 2 : 304 307.
25. Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007 5 (8 890 897.
26. Zeuzem S, Gane E, Liaw Y-F et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol 2009 51 (1 11 20.
27. Yuen M-F, Lai C-L. Prediction of treatment outcomes for lamivudine. J Gastroenterol Hepatol 2007 22 : 961 969.
28. Chan HL, Wong VW, Tse CH et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007 25 : 891 898.
29. Yuen M-F, Fong DY-T, Wong DK-H, Yuen JC-H, Fung J, Lai C-L. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007 46 : 1695 1703.